- The FDA has approved Abbott Laboratories (NYSE:ABT) latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
- The Navitor TAVI system is the latest addition to the company’s comprehensive transcatheter structural heart portfolio, offering less invasive treatment options.
- Aortic stenosis occurs when the aortic valve’s opening narrows, restricting blood flow to the body. Left untreated, it can lead to heart failure and death.
- Navitor features a unique fabric cuff (NaviSeal) to reduce or eliminate the backflow of blood around the valve frame, known as a paravalvular leak (PVL).
- Additionally, the new device is the only self-expanding TAVI system with leaflets within the native valve; this design can help improve access to coronary arteries to facilitate future procedures for treating coronary artery disease.
- The Navitor device is implanted using Abbott’s FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable, and accurate valve delivery and placement.
- Price Action: ABT shares are down 0.04% at $113.47 on the last check Tuesday.
Zscaler Q3 Earnings: Revenue, EPS Exceed Estimates Driven By ‘Growing Customer Interest’ In Zero Trust Exchange Platform
Zscaler said third-quarter revenue increased 32% year-over-year to $553.2 million, which beat the consensus estimate of $535.906 million, according to Benzinga Pro. The company reported quarterly adjusted earnings of 88 cents per share, beating analyst estimates of 66 cents per share.
